Contents

Current Pharmaceutical Biotechnology, Volume 2 - Number 4

Editorial

, 2(4): i

Antonio J. Grillo-Lopez, Anne McClure and Brian K. Dallaire


DOI: 10.2174/1389201013378554




Non-Hodgkins Lymphoma: Review of Conventional Treatments

, 2(4): 279 - 291

P. Multani, C.A. White and A. Grillo-Lopez


DOI: 10.2174/1389201013378581




The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy

, 2(4): 293 - 300

R.O. Dillman


DOI: 10.2174/1389201013378617




Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma

, 2(4): 301 - 311

A. J. Grillo-Lopez, B.K. Dallaire, A. McClure, R. Weaver, C. Varns, A. Wei, R. Allen, D. Lee, D. Shen, J. Leonard, P.Multani and C.A.White


DOI: 10.2174/1389201013378563




Toxin-Labeled Monoclonal Antibodies

, 2(4): 313 - 325

R.J. Kreitman


DOI: 10.2174/1389201013378635




Radioimmunotherapy of B-Cell NHL

, 2(4): 327 - 339

R.F. Meredith and S.J. Knox


DOI: 10.2174/1389201013378590




Zevalin™: 90Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin ’ s Lymphoma

, 2(4): 341 - 349

C. Krasner and R.M. Joyce


DOI: 10.2174/1389201013378545




Monoclonal Antibodies in the Treatment of Hematologic Malignancies: Radiation Dosimetry Aspects

, 2(4): 351 - 356

M.G. Stabin and A.B. Brill


DOI: 10.2174/1389201013378572




Antibody Therapy of Acute and Chronic Leukemias

, 2(4): 357 - 367

Spero R. Cataland, Margaret Lucas and John C. Byrd


DOI: 10.2174/1389201013378608




Future Approaches for Treating Hematologic Disease

, 2(4): 369 - 382

M. Reff, G. Braslawsky and N. Hanna


DOI: 10.2174/1389201013378626




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science